| Code | CSB-RA005165MB3HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to Tusamitamab, targeting CEACAM5 (Carcinoembryonic Antigen-Related Cell Adhesion Molecule 5), also known as CEA (carcinoembryonic antigen). CEACAM5 is a glycosylphosphatidylinositol-anchored cell surface glycoprotein that functions in cell adhesion, intracellular signaling, and immune modulation. This protein is normally expressed at low levels in healthy adult tissues, particularly in the gastrointestinal tract, but becomes significantly overexpressed in various epithelial malignancies. CEACAM5 plays a critical role in tumor progression, metastasis, and immune evasion, making it a well-established tumor-associated antigen in colorectal, pancreatic, gastric, lung, and breast cancers.
Tusamitamab is a therapeutic antibody designed to target CEACAM5-expressing tumor cells and has been investigated as part of antibody-drug conjugate strategies for cancer treatment. This biosimilar provides researchers with a valuable tool for investigating CEACAM5 biology, tumor microenvironment interactions, and antibody-based therapeutic mechanisms in oncology research. It supports studies exploring cancer cell behavior, immune checkpoint interactions, and novel immunotherapeutic approaches.
There are currently no reviews for this product.